Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): A multicenter phase II study

Annals of Oncology

Volumn 12, Issue 2, 2001, Pages 193-197

  Kakolyris, S ^a   Mavroudis, D ^a   Tsavaris, N ^b   Souglakos, J ^a   Tsiafaki, P ^c   Kalbakis, K ^a   Agelaki, S ^a   Androulakis, N ^a   Georgoulias, V ^a,d  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c SISMANOGLIO HOSPITAL   (Greece)

^d KAT HOSPITAL   (Greece)

Author keywords

Carboplatin; Paclitaxel; Salvage treatment; SCLC

Indexed keywords

CARBOPLATIN; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ALLERGY; ANEMIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEATH; DRUG RESPONSE; FEMALE; FLUID RETENTION; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; SALVAGE THERAPY; SURVIVAL RATE;

EID: 0035100918     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008322932251     Document Type: Article

References (24)

1. Cancer statistics, 1998
2. Small-cell lung cancer
3. Treatment of relapsed small-cell lung cancer
4. Chemotherapy resistance in small-cell lung cancer: Consequences for the clinician and future prospects
5. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosurea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small-cell lung cancer. A Southwest Oncology Group study
6. Cyclophosphamide, doxorubicin and vincristine in etoposide and cisplatin resistant small-cell lung cancer
7. Etoposide (VP-16) and cisplatin: An effective treatment for relapse in SCLC
8. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive stage small-cell lung cancer: A phase III trial of the Southern Cancer Study Group
9. Identification of new drugs in pretreated patients with small-cell lung cancer
10. Phase II study of paclitaxel in patients with extensive disease small-cell lung cancer: An Eastern Cooperative Group study
11. A phase II study of Taxol and G-CSF in previously untreated patients with extensive stage small-cell lung cancer
12. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
13. Carboplatin as second-line treatment for reccurent or progressive brain metastases from small-cell lung cancer
14. A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer
15. Synergistic interaction between cisplatin and Taxol in human ovarian carcinoma cells in vitro
16. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
17. Non-parametric estimation from incomplete observations
18. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
19. The multidrug resistance phenotype in clinical practice: Evaluation of cross-resistance to ifosphamide and messna after VP-16, doxorubicin and vincristine (VPAV) for small-cell lung cancer
20. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European Organization for research and treatment of cancer. Studies Group and New Development Office, and the Lung Cancer Cooperative
21. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer. A phase II trial
22. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin and etoposide: A non-cross resistant schedule